share_log

Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33

Moomoo 24/7 ·  Apr 24 05:28

Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and raises the price target from $30 to $33.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment